5-甲氧基-7-硝基-1H-吲哚-2-羧酸甲酯 | 1000341-42-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-甲氧基-7-硝基-1H-吲哚-2-羧酸甲酯
• 英文名称: 5-methoxy-7-nitro-1H-indole-2-carboxylic acid methyl ester
• 英文别名: methyl 5-methoxy-7-nitro-1H-indole-2-carboxylate
• CAS: 1000341-42-3
• 化学式: C₁₁H₁₀N₂O₅
• 分子量: 250.211
• InChiKey: VEZJPSMVGQWPNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  97.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-甲氧基-7-硝基-1H-吲哚-2-羧酸甲酯 在 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 生成 5-甲氧基-7-硝基-2-吲哚羧酸
  参考文献：
  名称：

  Structure-based design and biological evaluation of novel 2-(indol-2-yl) thiazole derivatives as xanthine oxidase inhibitors

  摘要：

  Inhibition of xanthine oxidase (XO) has obviously been a central concept for controlling hyperuricemia, which causes serious and painful inflammatory arthritis disease such as gout. We discovered a series of novel 2-(indol-2-yl) thiazole derivatives as XO inhibitors at the level of nanomolar activity. Structure-guided design using molecular modeling program (Accelrys Software program) provided an excellent basis for optimization of 2-(indol-2-yl) thiazole compounds. Structure-activity relationship indicated that hydrophobic alkoxy group (isopropoxy, cyclopentoxy) at 5-position and hydrogen binding acceptor (NO2, CN) at 7-position of indole ring appear as critical functional groups. Among the compounds, 2-(7-nitro-5-isopropoxy- indol-2-yl)-4-methylthiazole-5-carboxylic acid (9m) exhibits the most potent XO inhibitory activity (IC50 value: 5.1 nM) and the excellent uric acid lowering activity in potassium oxonate induced hyperuricemic rat model. (C) 2016 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2015.12.055
• 作为产物：
  描述：

  4-methoxy-2-nitrophenylhydrazine 在 sodium acetate 作用下， 生成 5-甲氧基-7-硝基-1H-吲哚-2-羧酸甲酯
  参考文献：
  名称：

  Structure-based design and biological evaluation of novel 2-(indol-2-yl) thiazole derivatives as xanthine oxidase inhibitors

  摘要：

  Inhibition of xanthine oxidase (XO) has obviously been a central concept for controlling hyperuricemia, which causes serious and painful inflammatory arthritis disease such as gout. We discovered a series of novel 2-(indol-2-yl) thiazole derivatives as XO inhibitors at the level of nanomolar activity. Structure-guided design using molecular modeling program (Accelrys Software program) provided an excellent basis for optimization of 2-(indol-2-yl) thiazole compounds. Structure-activity relationship indicated that hydrophobic alkoxy group (isopropoxy, cyclopentoxy) at 5-position and hydrogen binding acceptor (NO2, CN) at 7-position of indole ring appear as critical functional groups. Among the compounds, 2-(7-nitro-5-isopropoxy- indol-2-yl)-4-methylthiazole-5-carboxylic acid (9m) exhibits the most potent XO inhibitory activity (IC50 value: 5.1 nM) and the excellent uric acid lowering activity in potassium oxonate induced hyperuricemic rat model. (C) 2016 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2015.12.055

文献信息

• GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT
  申请人：Kim Soon Ha

  公开号：US20100267708A1

  公开（公告）日：2010-10-21

  The present invention relates to new compounds of formula (1) exhibiting excellent activity for glucokinase, and pharmaceutical compositions comprising the same as an active ingredient.

  本发明涉及公式（1）的新化合物，表现出对葡萄糖激酶的优异活性，并且包括该化合物作为活性成分的药物组合物。
• US8309586B2
  申请人：——

  公开号：US8309586B2

  公开（公告）日：2012-11-13
• [EN] GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT<br/>[FR] ACTIVATEURS DE LA GLUCOKINASE ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CES DERNIERS EN TANT QU'INGRÉDIENT ACTIF
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2009082152A2

  公开（公告）日：2009-07-02

  The present invention relates to new compounds of formula (1) exhibiting excellent activity for glucokinase, and pharmaceutical compositions comprising the same as an active ingredient.